Who is sponsoring NCT00289029?

NCT00289029 is sponsored by Bracco Diagnostics, Inc.

What drugs are being tested in NCT00289029?

Interventions: Iopamidol 370 mgI/mL.

What is the status of NCT00289029?

NCT00289029 is currently COMPLETED.

Last reviewed 2006-08-17 · How we verify

Visipaque and Isovue in Cardiac Angiography in Renally Impaired Patients

NCT00289029 Phase 4 COMPLETED

The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with moderate to severe renal insufficiency undergoing cardiac angiography. Serum creatinine will be measured before and up to 48-72 hours after the administration of the contrast agent to evaluate renal function.

Details

Lead sponsor	Bracco Diagnostics, Inc
Phase	Phase 4
Status	COMPLETED
Enrolment	400
Start date	2005-07
Completion	2006-06

Conditions

Interventions

Iopamidol 370 mgI/mL

Primary outcomes

Increase in SCr at 48-72 hours post dose

Countries

United States